InflammX Therapeutics, Inc.

Novel Breakthrough Drug Targeting the Pathological NLRP3 Inflammasome in Retinal Disease

Xiflam™

The lead product in Clinical Development, is Xiflam™, a once a day orally administered small molecule. The therapeutic target is the pathologically open Connexin43 (Cx43) Hemichannel. The pathological Cx43 hemichannel is responsible for inflammasome mediated autoinflammation in several disease states with significant unmet needs.

Current indications are Diabetic Macular Edema(DME)/Diabetic Chronic Kidney Disease (CKD) and the intermediate stage of Macular Degeneration (iAMD)

iAMD can be diagnosed at an early stage prior to patient’s losing vision and there is currently no approved pharmaceutical treatment. iAMD represents approximately 80% of patients with AMD

The therapeutic target is the pathologically open Connexin43 (Cx43) which is responsible for signaling, activation and perpetuation of the pro-inflammatory NLRP3 inflammasome - an Innate Immune System discovered in 2002

InflammX is developing Xiflam™, a small molecule for oral administration shown to selectively inhibit the pathologically open Cx43 hemichannel protein to modulate the dysregulated inflammasome and the resulting perpetuated autoinflammation.

 The Disruptive Potential of Xiflam™

·       An orally dosed alternative to monthly injections into the back of the eye (which is the currently approved treatment for the later stages of AMD and Diabetic Retinal Disease.

·       Treating patients with early stage disease (iAMD) before vision is lost, represents approximately 80% of all AMD patients.

·       There is no currently approved pharmacologic treatment for early stage disease – an enormous unmet need!

·       Diabetic Eye Disease – current treatment with intraocular injections of a drug called anti Vascular Endothelium Growth Factor (VEGF) fails approximately 50% of the time.

·       Orally dosed drug treats both eyes at the same time - both AMD and Diabetic Eye Disease affects both eyes.

·       An oral, rather than an intraocular treatment, removes the risk of vision loss in eyes with good vision due to the potential for infection/inflammation with injections.